Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
Professor of Medicine, Environmental Medicine, Microbiology & Immunology
Director, Pulmonary Function Labs
Pulmonary and Critical Care Division
University of Rochester Medical Center (URMC)
Rochester, New York
The educational design of this activity addresses the needs of pulmonology and clinical immunology clinicians who manage patients with severe asthma.
When asthma remains uncontrolled, patients are at increased risk for death, have lower lung function, experience more frequent exacerbations, suffer from higher levels of medical and mental distress, and are more likely to miss work or school. This Monday Morning Joe™ activity has been designed as a unique, coffee-talk style format that offers education on four key topics related to the management of severe asthma: 1) underlying mechanisms of severe disease; 2) addressing underdiagnosis with proper assessment; 3) relevance of mucus plugs with respect to patient outcomes; and 4) translating the efficacy of biologic therapies to shared decision-making. This engaging platform promises to provide concise and practical information that may help to reduce patient asthma burdens and close practice gaps within asthma treatment.
After completing this activity, the participant should be better able to:
- Discuss asthma pathophysiology, focusing on processes that cause airway obstruction, inflammation, mucus plugging, and hyperresponsiveness
- Evaluate patients with asthma for disease severity, degree of control, and treatment responses
- Describe recent evidence examining mucus plugs in patients with asthma, including potential consequences, evaluation strategies, and implications for treatment
- Overcome barriers related to the use of biologic therapies for patients with severe asthma
Physician Accreditation Statement
Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integritas designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationships
Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Reynold A. Panettieri, Jr., MD: Consulting Fees: AstraZeneca plc, Genentech, Praesidia Biotherapeutics, RIFM; Contracted Research: ACTIV-1, AGOMED, AstraZeneca plc, Janssen Pharmaceuticals, Medimmune, LLC, RIFM, Teva Pharmaceutical Industries Ltd., Vault Health; Speakers' Bureaus: AstraZeneca plc, Merck & Co., Inc., Sanofi S.A.
Steve N. Georas, MD: Consulting Fees: ARS Pharma, AstraZeneca plc, Chiesi USA, Inc.
The planners and managers at Integritas Communications have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Integritas Contact Information
For questions about this activity, please contact Integritas Communications at firstname.lastname@example.org.